Advertisement
Advertisement
FHTX
Foghorn Therapeutics Inc. Common Stock
4.01
USDSponsored
-0.07
-1.72%
Jun 25, 15:46 UTC -4
Open
FHTX Earnings Reports
Positive Surprise Ratio
FHTX beat 15 of 23 last estimates.
65%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$6.11M
/-$0.25
Implied change from Q1 26 (Revenue/ EPS)
+87.17%
/-10.71%
Implied change from Q2 25 (Revenue/ EPS)
-19.08%
/-10.71%
Foghorn Therapeutics Inc. Common Stock earnings per share and revenue
On May 07, 2026, FHTX reported earnings of -0.28 USD per share (EPS) for Q1 26, beating the estimate of -0.31 USD, resulting in a 6.78% surprise. Revenue reached 3.27 million, compared to an expected 7.59 million, with a -56.94% difference. The market reacted with a -10.26% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.25 USD, with revenue projected to reach 6.11 million USD, implying an decrease of -10.71% EPS, and increase of 87.17% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Grace Therapeutics, Inc. Common Stock
Report Date
Jun 18, 2026 For Q4 26
Estimate
-$0.23
Actual
-$0.06
Surprise
+74.42%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were Foghorn Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Foghorn Therapeutics Inc. Common Stock reported EPS of -$0.28, beating estimates by 6.78%, and revenue of $3.27M, -56.94% below expectations.
How did the market react to Foghorn Therapeutics Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -10.26%, changed from $4.68 before the earnings release to $4.20 the day after.
When is Foghorn Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Foghorn Therapeutics Inc. Common Stock's next earnings report?
Based on 8
analysts, Foghorn Therapeutics Inc. Common Stock is expected to report EPS of -$0.25 and revenue of $6.11M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement